Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Women, Sympathetic Nervous System, Aging, Blood Flow
Interventions: Norepinephrine, Isoproterenol, Acetylcholine, Nitroprusside, Estrogen; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 18 Years to 70 Years · Female only
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Anemia, Myelodysplastic Syndrome
Interventions: Deferasirox, Laboratory Biomarker Analysis; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Anemia
Interventions: ferumoxytol or oral iron; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 50
States / cities: Phoenix, Arizona • Tempe, Arizona • Los Angeles, California + 42 more

Conditions: Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions: Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage); Drug
Lead sponsor: ApoPharma; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Chicago, Illinois • New York, New York

Conditions: Iron-deficiency, Heart Failure With Preserved Ejection Fraction
Interventions: Ferric Derisomaltose 1000 Mg in 100 mL INTRAVENOUS SOLUTION [Monoferric], Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Iron Deficiency Anemia
Interventions: Ferric Carboxymaltose (FCM), Ferrous Sulfate Tablets, IV Iron (standard of care); Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 997 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Norristown, Pennsylvania

Conditions: Heart Failure, Iron Deficiency Anemia
Interventions: Sodium ferric gluconate; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Iron Deficiency
Interventions: ionic iron, heme iron polypeptide; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 7 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Anaemia, Aspergillosis, Allergic Bronchopulmonary
Interventions: Daprodustat, rhEPO, Placebo, Iron therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 2,964 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 126
States / cities: Huntsville, Alabama • Pine Bluff, Arkansas • Anaheim, California + 103 more

Conditions: Chronic Kidney Diseases, Iron Deficiency Anemia
Interventions: KRX-0502; Drug
Lead sponsor: Keryx Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 28
States / cities: Phoenix, Arizona • Chula Vista, California • El Centro, California + 23 more

Conditions: Anemia
Interventions: Venofer, Ferrous Sulfate; Drug
Lead sponsor: American Regent, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Valley Forge, Pennsylvania

Conditions: Iron-deficiency
Interventions: Ferric Carboxymaltose, Placebo, 31P MRS/MRI; Drug · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Cancer of Lymph Node
Interventions: Feraheme, Magnetic Resonance Imaging (MRI); Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Thalassemia, Iron Overload
Interventions: Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO); Drug
Lead sponsor: Elliott Vichinsky; Other
Eligibility: 8 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: Iron Deficiency, Iron Deficiency Anemia (IDA), Vitamin D Deficiency, Vitamin D Insufficiency, Low Energy Availability, Bone Density
Interventions: Iron and Vitamin D Deficiencies Correction; Dietary Supplement
Lead sponsor: Morehouse School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Iron Deficiency Anemia
Interventions: Iron isomaltoside 1000, Natrium Chloride 0,9%; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pantothenate Kinase-associated Neurodegeneration (PKAN)
Interventions: Not listed
Lead sponsor: Susan J. Hayflick; Other
Eligibility: 7 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Liver Neoplasms, Hepatic Cirrhosis, Hepatic Carcinoma, Liver Cancer, Liver Metastases, Liver Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatic Atrophy
Interventions: Ferumoxytol injection; Drug
Lead sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute); Other
Eligibility: 18 Years to 89 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anemia, Iron Deficiency, Iron Overload
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Ithaca, New York

Conditions: Epilepsy
Interventions: Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Iron Deficiency
Interventions: Not listed
Lead sponsor: Cornell University; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions: Nicardipine and Nipride; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 70 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Sclerosis
Interventions: Rebif; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Acute Heart Failure
Interventions: Sodium nitroprusside, Dobutamine, Furosemide; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Early Neurovascular Adaptations in Aging Women

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

Ferumoxytol Versus Oral Iron in the Treatment of Anemia in Hemodialysis Patients

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Impact of Intravenous Iron Repletion On Mechanisms of Exercise InTolerance in HFpEF (IRONMET-HFpEF)

Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)

Short-Term Effects & Safety of an Accelerated Intravenous Iron Regimen in Patients With Heart Failure

A Pilot Study Comparing Tolerance of Oral Heme Iron Polypeptide With Oral Ionic Iron

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

KRX-0502 (Ferric Citrate) in Subjects With NDD-CKD and IDA (The COMPASS Trial)

Comparison of Safety and Efficacy of Intravenous Iron Versus Oral Iron in Chronic Renal Failure Subjects With Anemia

Ferric Carboxymaltose to Improve Skeletal Muscle Metabolism in Heart Failure Patients With Functional Iron Deficiency

Clinical and Technical Feasibility of a Ultrasuperparamagnetic Nanoparticle Iron Oxide (USPIO)-Enhanced Magnetic Resonance Lymph Node Imaging

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Collegiate Athlete Study

A Randomized, Double-blind, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Against Placebo

Brain Perfusion in Pantothenate Kinase-associated Neurodegeneration (PKAN)

Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers

Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption

Imaging Neuroinflammation in Epilepsy With Ferumoxytol MRI

Relative Contributions of Red Cell Catabolism and Dietary Absorption to Fetal Iron Accretion During Pregnancy

Safety and Efficacy of Nicardipine for the Control of Blood Pressure After SAH

Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial

Intravenous Vasodilator vs. Inotropic Therapy in Patients With Heart Failure